Annalisa Chiappella

Medicine & Life Sciences

1. Mantle-Cell Lymphoma 100%
2. Lymphoma, Large B-Cell, Diffuse 36%
3. Stem Cell Transplantation 35%
4. Peripheral T-Cell Lymphoma 30%
5. PCI 32765 30%
6. Allogeneic Cells 29%
7. Survival 25%
8. Progression-Free Survival 24%
9. Anaplastic Large-Cell Lymphoma 24%
10. Rituximab 19%
11. T-Lymphocytes 18%
12. Anaplastic Lymphoma Kinase 18%
13. Lenalidomide 18%
14. Adoptive Immunotherapy 17%
15. Homologous Transplantation 15%
16. Hematopoietic Stem Cell Transplantation 14%
17. Hematology 13%
18. Cytarabine 12%
19. Drug Therapy 11%
20. Agammaglobulinaemia Tyrosine Kinase 11%
21. Confidence Intervals 11%
22. Chimeric Antigen Receptors 11%
23. Lymphoma 10%
24. Prospective Studies 10%
25. Maintenance 9%
26. B-Cell Lymphoma 9%
27. Therapeutics 8%
28. Central Nervous System 8%
29. Anthracyclines 8%
30. Lymphoproliferative Disorders 7%
31. Elderly 7%
32. Mutation 7%
33. romidepsin 7%
34. CD19 Antigens 7%
35. Bendamustine Hydrochloride 6%
36. Bone Marrow Diseases 6%
37. Survival Rate 6%
38. Liver X Receptors 6%
39. Cohort Studies 6%
40. Null Lymphocytes 5%
41. Pharmaceutical Preparations 5%
42. Histiocytes 5%
43. Recurrence 5%
44. Neoplasms 5%